Literature DB >> 33413409

YAP manipulates proliferation via PTEN/AKT/mTOR-mediated autophagy in lung adenocarcinomas.

Wei Xu1, Mingjiong Zhang1, Yue Li1,2, Yu Wang1, Kai Wang1, Qiaoyu Chen3, Runjie Zhang1, Weiwei Song1, Qiqing Huang1, Weihong Zhao1, Jianqing Wu4.   

Abstract

BACKGROUND: Autophagy is a double-edged sword during the initiation and progression of multiple tumors. The Hippo pathway effector YAP has been proved to be involved in autophagy processes. The present study aimed to investigate how YAP regulates cell proliferation via autophagy in lung adenocarcinomas (LUAD).
METHODS: Data of LUAD chip GSE43458 was obtained from Gene Expression Omnibus (GEO). RT-qPCR and Western blot were performed to assess YAP expression in LUAD cell lines. CCK-8 assay, xenograft tumor model, immunochemistry and GFP-mRFP-LC3 fusion proteins were utilized to evaluate the effect of YAP on autophagy of LUAD cells in vitro and in vivo. Autophagy inhibitor treatment and rescue experiments were carried out to elucidate the mechanism by which YAP manipulates autophagy in LUAD cells.
RESULTS: YAP was significantly overexpressed in samples of LUAD patients and its expression level is related to 5-year survival. YAP manipulated the proliferation and autophagy in A549 and H1299 LUAD cells. YAP could induce activation of Akt/mTOR signaling pathway via suppressing PTEN in a Hippo-pathway-dependent manner. 3-Methyladenine impeded autophagy flux and promoted the proliferation in vitro and in vivo.
CONCLUSIONS: Hippo pathway critical transcriptional coactivators YAP manipulates the proliferation of lung adenocarcinoma, which is regulated by PTEN/AKT/mTOR autophagic signaling.

Entities:  

Keywords:  Autophagy; LUADs; PTEN/AKT/mTOR; YAP

Year:  2021        PMID: 33413409      PMCID: PMC7791871          DOI: 10.1186/s12935-020-01688-9

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  46 in total

Review 1.  The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal.

Authors:  Bin Zhao; Karen Tumaneng; Kun-Liang Guan
Journal:  Nat Cell Biol       Date:  2011-08-01       Impact factor: 28.824

2.  TAZ inhibition restores sensitivity of cisplatin via AKT/mTOR signaling in lung adenocarcinoma.

Authors:  Wei Xu; Yunyan Wei; Yue Li; Yuan Yin; Weiwei Yuan; Yan Yang; Weihong Zhao; Jianqing Wu
Journal:  Oncol Rep       Date:  2017-07-24       Impact factor: 3.906

Review 3.  The Hippo Pathway: Biology and Pathophysiology.

Authors:  Shenghong Ma; Zhipeng Meng; Rui Chen; Kun-Liang Guan
Journal:  Annu Rev Biochem       Date:  2019-12-19       Impact factor: 23.643

4.  Eriocalyxin B, a novel autophagy inducer, exerts anti-tumor activity through the suppression of Akt/mTOR/p70S6K signaling pathway in breast cancer.

Authors:  Xunian Zhou; Grace Gar-Lee Yue; Andrew Man-Lok Chan; Stephen Kwok-Wing Tsui; Kwok-Pui Fung; Handong Sun; Jianxin Pu; Clara Bik-San Lau
Journal:  Biochem Pharmacol       Date:  2017-06-30       Impact factor: 5.858

5.  CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma.

Authors:  Thibaud P Coroller; Patrick Grossmann; Ying Hou; Emmanuel Rios Velazquez; Ralph T H Leijenaar; Gretchen Hermann; Philippe Lambin; Benjamin Haibe-Kains; Raymond H Mak; Hugo J W L Aerts
Journal:  Radiother Oncol       Date:  2015-03-04       Impact factor: 6.280

Review 6.  p53 and ARF: unexpected players in autophagy.

Authors:  Gregor M Balaburski; Robert D Hontz; Maureen E Murphy
Journal:  Trends Cell Biol       Date:  2010-03-19       Impact factor: 20.808

Review 7.  The biology of YAP/TAZ: hippo signaling and beyond.

Authors:  Stefano Piccolo; Sirio Dupont; Michelangelo Cordenonsi
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

Review 8.  YAP/TAZ at the Roots of Cancer.

Authors:  Francesca Zanconato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Cancer Cell       Date:  2016-06-13       Impact factor: 31.743

9.  TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.

Authors:  Weiwei Yuan; Wei Xu; Yan Li; Wei Jiang; Yue Li; Qiqing Huang; Bo Chen; Shuangshuang Wu; Yu Wang; Weiwei Song; Weihong Zhao; Jianqing Wu
Journal:  Cell Death Dis       Date:  2019-03-25       Impact factor: 8.469

Review 10.  Recent insights into the function of autophagy in cancer.

Authors:  Ravi Amaravadi; Alec C Kimmelman; Eileen White
Journal:  Genes Dev       Date:  2016-09-01       Impact factor: 11.361

View more
  5 in total

1.  S100A14 inhibits cell growth and epithelial-mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway.

Authors:  Shaoqin Jiang; Yaru Zhu; Zhenlin Chen; Zhangcheng Huang; Bingqiao Liu; Yue Xu; Zhihao Li; Zequn Lin; Mengqiang Li
Journal:  Hum Cell       Date:  2021-04-23       Impact factor: 4.174

2.  CCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal transition.

Authors:  Tao Fan; Shuofeng Li; Chu Xiao; He Tian; Yujia Zheng; Yu Liu; Chunxiang Li; Jie He
Journal:  Int J Biol Sci       Date:  2022-06-27       Impact factor: 10.750

Review 3.  mTOR Signaling Components in Tumor Mechanobiology.

Authors:  Antonios N Gargalionis; Kostas A Papavassiliou; Efthimia K Basdra; Athanasios G Papavassiliou
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

4.  Integrative bioinformatics and experimental analysis revealed TEAD as novel prognostic target for hepatocellular carcinoma and its roles in ferroptosis regulation.

Authors:  Xinxin Ren; Xiang Wang; Yuanliang Yan; Xi Chen; Yuan Cai; Qiuju Liang; Bi Peng; Zhijie Xu; Qingchun He; Fanhua Kang; Jianbo Li; Wenqin Zhang; Qianhui Hong; Jinwu Peng; Muzhang Xiao
Journal:  Aging (Albany NY)       Date:  2022-01-25       Impact factor: 5.682

5.  High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma.

Authors:  Jianjun Xu; Zhe Su; Xiang Cheng; Shaobo Hu; Wenjie Wang; Tianhao Zou; Xing Zhou; Zifang Song; Yun Xia; Yang Gao; Qichang Zheng
Journal:  Cancer Cell Int       Date:  2022-03-11       Impact factor: 5.722

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.